实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (5): 719-722.doi: 10.3969/j.issn.1672-5069.2025.05.020

• 自身免疫性肝病 • 上一篇    下一篇

自身免疫性胰腺炎合并IgG4相关硬化性胆管炎患者临床特征分析*

刘家阳, 鲁俊, 李良   

  1. 230011 合肥市 安徽医科大学附属合肥医院/合肥市第二人民医院普外科
  • 收稿日期:2024-01-19 出版日期:2025-09-10 发布日期:2025-09-19
  • 通讯作者: 李良,E-mail:waikeliliang@sina.com
  • 作者简介:刘家阳,男,34岁,硕士研究生。E-mail:ljy1230317@163.com

Clinical feature of patients with IgG4-related sclerosing cholangitis and concomitant autoimmune pancreatitis: An analysis of 19 cases

Liu Jiayang, Lu Jun, Li Liang, et al   

  1. Department of General Surgery, Second People’s Hospital Affiliated to Anhui Medical University, Hefei 230011, Anhui Province, China
  • Received:2024-01-19 Online:2025-09-10 Published:2025-09-19

摘要: 目的 探讨自身免疫性胰腺炎(AIP)合并IgG4相关硬化性胆管炎(IgG4-SC)患者临床特征,以提高临床对IgG4相关性疾病(IgG4-RD)的理解和处理。方法 2020年11月~2023年4月我院诊治的AIP患者28例和AIP合并IgG4-SC患者19例,常规行肝活检和腹部CT检查,采用ELISA法检测血清IgG和IgG4,计算IgG4-RD疾病活动度应答指数(RI)。给予泼尼松或/和熊去氧胆酸(UDCA)治疗。结果 AIP合并IgG4-SC组患糖尿病比例、器官受累数目和RI分别68.4%、3.0(2.5,4.5)个和12.5(12.0,14.5),均显著高于单纯AIP组【分别为35.7%、2.0(1.0,2.5)个和7.0(5.0,8.0),P<0.05】;AIP合并IgG4-SC组上腹痛发生率为73.7%,显著高于单纯AIP组的42.9%(P<0.05);AIP合并IgG4-SC组血清GGT、ALP、IgG、淀粉酶和脂肪酶水平分别为574.7(76.8,965.2)U/L、438.0(274.4,638.7)U/L、141.6(134.7,208.5)g/L、38.5(29.7,79.2)U/L和49.3(36.1,108.5)U/L,均显著高于单纯AIP组【分别为298.8(37.5,685.3)U/L、168.5(109.4,374.3)U/L、45.3(30.5,69.4)g/L、16.6(10.6,28.0)U/L和14.5(8.5,25.8)U/L,P<0.05】;AIP合并IgG4-SC组弥漫性胰腺肿大比例、胰腺结石或钙化比例和肝内胆管壁增厚比例分别为78.9%、15.8%和15.8%,均显著高于单纯AIP组的46.4%、3.6%和3.6% (P<0.05)。结论 AIP合并IgG4-SC患者病情可能较为复杂,需要临床缜密的评估和处理,应用皮质激素联合UDCA治疗,短期预后良好。

关键词: IgG4相关硬化性胆管炎, 自身免疫性胰腺炎, 临床特征, 预后

Abstract: Objective The aim of this study was to summarize clinical feature of patients with IgG4-related sclerosing cholangitis (IgG4-SC) and concomitant autoimmune pancreatitis (AIP). Methods 28 patients with AIP and 19 patients with AIP and concomitant IgG4-SC were encountered in our hospital between November 2020 and April 2023, and all underwent liver biopsies and abdominal CT scan. Serum IgG and IgG4 levels were detected by ELISA, and IgG4-RD activity responder index (RI) were calculated. Patients were treated by prednisone and/or ursodeoxycholic acid (UDCA). Results Percentage of concomitant diabetes, involved organ and RI in patients with AIP and IgG4-SC were 68.4%, 3.0(2.5, 4.5) and 12.5(12.0, 14.5), all significant higher than [35.7%, 2.0(1.0, 2.5) and 7.0(5.0, 8.0), respectively, P<0.05] in patients with AIP; incidence of abdominal pain in patients with AIP and IgG4-SC was 73.7%, much higher than 42.9%(P<0.05) in patients with AIP; serum GGT, ALP, IgG, amylase and lipase levels in patients with AIP and IgG4-SC were 574.7(76.8, 965.2)U/L, 438.0(274.4, 638.7)U/L, 141.6(134.7, 208.5)g/L, 38.5(29.7, 79.2)U/L and 49.3(36.1, 108.5)U/L, all much higher than [298.8(37.5, 685.3)U/L, 168.5(109.4, 374.3)U/L, 45.3(30.5, 69.4)g/L, 16.6(10.6, 28.0)U/L and 14.5(8.5, 25.8)U/L, respectively, P<0.05] in patients with AIP; percentages of diffuse pancreatic enlargement, pancreatic stones or calcification and intrahepatic bile duct wall thickening in patients with AIP and IgG4-SC were 78.9%, 15.8% and 15.8%, all much higher than 46.4%, 3.6% and 3.6% (P<0.05) in patients with AIP. Conclusion Autoimmune pancreatitis and concomitant IgG4-SC might be clinically sophisticated, and clinicians should assess the disease carefully. We recommend prednisone and UDCA treatment for them.

Key words: IgG4-related sclerosing cholangitis, Autoimmune pancreatitis, Clinical feature, Prognosis